An epidemiological, developmental and clinical overview of cannabis use during pregnancy by El Marroun, H. (Hanan) et al.
Contents lists available at ScienceDirect
Preventive Medicine
journal homepage: www.elsevier.com/locate/ypmed
Review Article
An epidemiological, developmental and clinical overview of cannabis use
during pregnancy
Hanan El Marrouna,b,c,⁎, Qiana L. Brownd,e,f, Ingunn Olea Lundg, Victoria H. Coleman-Cowgerh,
Amy M. Loreei, Devika Chawlaj, Yukiko Washiok
a Department of Child and Adolescent Psychiatry, Erasmus MC, Sophia Children's Hospital, 3000 CB Rotterdam, the Netherlands
bDepartment of Psychology, Education and Child Studies, Erasmus University Rotterdam, 3000 DR Rotterdam, the Netherlands
c Department of Pediatrics, Erasmus MC, Sophia Children's Hospital, 3000 CB Rotterdam, the Netherlands
d School of Social Work, Rutgers University, 536 George Street, New Brunswick, NJ 08901, USA
e Department of Urban-Global Public Health, School of Public Health, Rutgers University, 683 Hoes Lane West, Piscataway, NJ 08854, USA
f Center for Prevention Science, School of Social Work, Rutgers University, 390 George Street, New Brunswick, NJ 08901, USA
g Department for Mental Disorders, The Norwegian Institute of Public health, PO Box 4404, Nydalen, N-0403 Oslo, Norway.
h Individual and Population Health, Battelle, 6115 Falls Road, Suite 200, Baltimore, MD 21209, USA
i Center for Health Policy & Health Services Research, Henry Ford Health System, One Ford Place, Detroit, MI 48202, USA
jDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
k Christiana Care Health System/University of Delaware, Newark, DE, USA
A R T I C L E I N F O
Keywords:
Maternal exposure
Prenatal exposure delayed eﬀects
Cannabis
Marijuana abuse
Clinical medicine
Preventive medicine
A B S T R A C T
The objective of the current narrative literature review is to provide an epidemiological, developmental and
clinical overview on cannabis use during pregnancy. Cannabis use in pregnancy poses major health concerns for
pregnant mothers and their developing children. Although studies on the short- and long-term consequences of
prenatal cannabis exposure are increasing, ﬁndings have been inconsistent or diﬃcult to interpret due to
methodological issues. Thus, consolidating these ﬁndings into clinical recommendations based on the mixed
studies in the literature remains a challenge. Synthesizing the available observational studies is also diﬃcult,
because some of the published studies have substantial methodological weaknesses. Improving observational
studies will be an important step toward understanding the extent to which prenatal exposure to cannabis
inﬂuences neurodevelopment in the oﬀspring. Therefore, further research on prenatal cannabis exposure and the
long-term consequences to oﬀspring health in representative samples are needed to guide and improve clinical
care for pregnant women and their children. Future research should also investigate the role of policies on
prenatal cannabis use.
Cannabis use during pregnancy is an important health issue as it
may aﬀect the health of pregnant women and their oﬀspring. The idea
of this narrative review of the literature was raised during round table
discussions on cannabis use in pregnancy at the 10th Annual
International Women's and Children's Health and Gender (InWomen's)
Group Conference in June 2017 in Montreal. The mission of the
InWomen's Group is to address issues in substance use among women,
children, youth, and Lesbian Gay Bisexual Transgender Queer (LGBTQ)
populations, and also examine gender diﬀerences globally. Issues that
were addressed during this round table discussion included: What is the
current scientiﬁc knowledge on prenatal cannabis use? How can we
improve the scientiﬁc information and knowledge transfer? And, what
are problems in clinical practice? Therefore, the purpose of the current
paper is to provide an epidemiological, developmental, and clinical
overview of published research on cannabis use during pregnancy. In
addition, the authors of this paper suggest directions for future research
and oﬀer evidence-based clinical guidance for providers working with
reproductive age women.
1. Epidemiological overview
Rates of cannabis use among pregnant women are increasing just as
fast as they are among non-pregnant women of reproductive age
(Brown et al., 2017b). For example, in a US nationally representative
study among reproductive-age women 18 to 44 years old, numbers
showed that the prevalence of current cannabis use (i.e. past month
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use) in pregnancy increased from 2.37% in 2002 to 3.85% in 2014,
while the prevalence of cannabis use among non-pregnant women in-
creased from 6.29% in 2002 to 9.27% in 2014 (Brown et al., 2017b).
Considering the lower prevalence of cannabis use among pregnant
women, compared to their non-pregnant counterparts, pregnancy might
be viewed as a protective factor. However, this view may be overly
liberal, given that rise in cannabis use over time appears to be similar
between pregnant and non-pregnant women in the US (Brown et al.,
2017b). In the Netherlands, a country that is considerably tolerant to-
ward the use of cannabis, maternal cannabis use during pregnancy was
approximately 3% in 2002 to 2006 (El Marroun et al., 2008). Un-
fortunately, there are no recent prevalence estimates of prenatal can-
nabis use in the Netherlands. Data suggests that women using cannabis
during pregnancy are often daily users (El Marroun et al., 2008; Ko
et al., 2015), and, cannabis-using pregnant women are more likely to
meet criteria for cannabis use disorders relative to non-pregnant
women of reproductive age (18.1% as compared to 11.4% in non-
pregnant reproductive-age women) (Ko et al., 2015).
Given the increase of cannabis use among pregnant women and
concerns about the potential negative fetal and child health con-
sequences associated with prenatal cannabis exposure (Gunn et al.,
2016), it is important to understand who may be at risk for using
cannabis while pregnant. Younger age has been consistently associated
with increased prenatal cannabis use (Brown et al., 2017b). For ex-
ample, from 2002 to 2014 in a representative sample in the US, can-
nabis use during pregnancy was higher among 18 to 25 year-olds
(7.47%) as compared to 26 to 44 year-olds (2.12%) (Brown et al.,
2017b). In addition, low income or socioeconomic disadvantage; being
divorced, separated, widowed, or never married; and tobacco, alcohol,
and other illicit drug use were associated with increased past-year
cannabis use (i.e. cannabis use during or around the time of pregnancy)
among pregnant women (El Marroun et al., 2008; Ko et al., 2015). In
addition, past-year psychiatric diagnoses, including any anxiety or
mood disorder, antisocial personality disorder, and borderline person-
ality disorder, have been associated with increased past-year cannabis
use among pregnant women as well (Brown et al., 2017a). Delinquency
and childhood trauma have also been associated with cannabis use
during pregnancy (El Marroun et al., 2008). In addition to demographic
risk factors (being married or single), the behaviours of others family
members or friends in the social network of individuals can also pose a
risk for prenatal cannabis use. For example, having a partner who uses
cannabis is one of the strongest predictors of cannabis use during
pregnancy (El Marroun et al., 2008).
Furthermore, mothers who use cannabis during pregnancy may also
use it while breastfeeding, but very little information is available on this
topic. A recent survey indicated that approximately 15% of breast-
feeding mothers reported past year cannabis use in the US (Bergeria and
Heil, 2015). It is important to further study breastfeeding and cannabis
use as infants receiving breast milk of cannabis-using mothers are ex-
posed at approximately 0.8% of maternal exposure (Djulus et al., 2005).
2. Developmental overview
Studies investigating prenatal cannabis exposure and pregnancy and
birth outcomes are increasing. For example, in a systematic review and
meta-analyses, it has been shown that children exposed to cannabis in
utero have lower birth weight (but no diﬀerence in neonatal length or
head circumference) and they need placement in the neonatal intensive
care unit (Gunn et al., 2016). In addition, women who used cannabis
had higher odds of anemia compared to women who did not use can-
nabis while pregnant (Gunn et al., 2016). However, no associations
have been found between prenatal cannabis exposure and other birth
outcomes such as stillbirth (Varner et al., 2014; Warshak et al., 2015) or
fetal distress (Gunn et al., 2016).
However, information on neurodevelopmental outcomes in children
exposed to cannabis in utero is sparse and has been researched in a few
longitudinal cohorts worldwide (reviewed in Calvigioni et al., 2014;
Huizink, 2014; Jutras-Aswad et al., 2009; McLemore and Richardson,
2016; Trezza et al., 2008): a) The Ottawa Prenatal Prospective Study
(OPPS) in Ottawa, Canada; b) The Maternal Health Practices and Child
Development Study (MHPCD) in Philadelphia, the US; and (c) The
Generation R Study in Rotterdam, the Netherlands. Oﬀspring in the
OPPS were followed until the ages 18–22 years (with expected attri-
tion); follow-up data of the MHPCD study have been reported up to the
age of 14; data reported on the children from the Generation R study is
up to the age of 8 years, and data collection is still ongoing. These re-
views (reviewed in Calvigioni et al., 2014; Huizink, 2014; Jutras-Aswad
et al., 2009; McLemore and Richardson, 2016; Trezza et al., 2008) show
that, at birth, newborns show increased tremors accompanied by ex-
aggerated and prolonged startles or altered sleep patterns. In infancy,
children exposed to cannabis in utero are more likely to have problems
with executive functioning including lower memory scores, as well as
more attention problems, hyperactivity and impulsivity in early child-
hood. In the longer-term, adolescents exposed to cannabis during
pregnancy have a higher risk of problems with executive functioning,
and are also more likely to develop emotional and behavioral problems,
such as depression and delinquent behavior. However, studies are in-
consistent; the OPSS found no association between cannabis exposure
in pregnancy and infant mental development at 1 year. Likewise, the
MHPCD cohort found no association of prenatal cannabis use and the
mental scores of the Bayley Scales of Infant Development (reviewed in
Huizink, 2014; Trezza et al., 2008). In addition, prenatal cannabis use
has been related to more advanced motor skills (reviewed in Huizink,
2014).
Neurodevelopmental changes may be underlying these problems,
and structural and functional neuroimaging studies suggest that the
frontal part of the brain might develop and function diﬀerently in
children and adolescents exposed to cannabis as compared to non-ex-
posed controls (El Marroun et al., 2016; Smith et al., 2006; Smith et al.,
2010). These studies suggest that the endocannabinoid system plays an
essential role in the ontogeny of the nervous system during fetal brain
development and that early gestational exposure to cannabis is able to
induce lasting but subtle neurodevelopmental alterations. Indeed, a
growing body of evidence indicates that the endocannabinoid system
plays a role in a broad array of critical neurodevelopmental processes,
from early neural stem cell survival and proliferation to the migration
and diﬀerentiation of both glial and neuronal lineages as well as neu-
ronal connectivity and synaptic function (Lubman et al., 2015). More-
over, animal studies are in agreement with these ﬁndings, as they show
that exposure to low doses of THC in a narrow temporal window during
prenatal development (embryonic day 12.5 to 16.5) negatively impacts
mouse cortical development (de Salas-Quiroga et al., 2015), and this, in
turn, has long-term functional consequences on mature oﬀspring (Wu
et al., 2011).
Nevertheless, while information on prenatal cannabis use and fetal
outcomes is becoming increasingly available, little information is pre-
sent on maternal cannabis use during pregnancy and the long-term
physiological and neurodevelopmental consequences in oﬀspring.
Although the number of high-quality studies is increasing, many of the
published studies are limited by methodological problems. These
methodological problems include small sample sizes, biases (e.g. se-
lection bias, confounding or misclassiﬁcation are often major limita-
tions), have diﬀerent study designs (e.g. cross-sectional, retrospective
or prospective studies), assessment of diﬀerent outcomes, and diﬀer-
ences in exposure assessment (self-report or urinalysis) (Beatty et al.,
2012; El Marroun et al., 2011) making it diﬃcult to synthesize in-
formation and make valid conclusions regarding the health eﬀects of
prenatal cannabis exposure. In a recent report of the National Acade-
mies of Sciences (National Academies of Sciences, Engineering, and
Medicine, et al., 2017), the committee did not identify a good- or fair-
quality systematic review that reported on the association between
prenatal cannabis exposure and later outcomes for children and thus
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reported on the studies performed in three diﬀerent cohorts (ACOG,
2011). Further, cannabis use is often combined with smoking tobacco,
which makes disentangling the speciﬁc eﬀect of cannabis only diﬃcult.
These methodological diﬀerences across studies must be kept in mind as
they may contribute to the inconsistent ﬁndings. Notably, in the past
decade, levels of Δ9-tetrahydrocannabinol (THC) in cannabis products
have increased (Dujourdy and Besacier, 2017; Niesink et al., 2015), and
high potency products such as butane hash oil have become available
(Miller et al., 2016). These potent products may inﬂuence fetal devel-
opment, as cannabis metabolites are able to pass the placental barrier.
In summary, there is substantial evidence of an association between
prenatal cannabis use and lower birth weight in oﬀspring. However, the
long-term eﬀects (> 10 years) of prenatal cannabis exposure on oﬀ-
spring neurodevelopmental outcomes (for example, cognitive func-
tioning or academic achievement) are less well established as there are
only three longitudinal cohorts that measured diﬀerent outcomes at
diﬀerent ages in the oﬀspring. Specially, longitudinal studies that ex-
amine the association of prenatal cannabis exposure on health and
neurodevelopment prospectively through childhood and adolescence,
rather than just infant years, are needed to understand the potential
long-term consequences. Thus, continued research on the potential
consequences of prenatal cannabis exposure on other fetal and child
health outcomes is necessary.
3. Considerations for future research
First, to capture possible long-term outcomes, prospective long-
itudinal studies with longer follow-up periods are necessary. The
follow-up in each study was at least 8 years and some outcomes of in-
terest, such as academic achievements, labor participation, de-
linquency, schizophrenia, psychotic symptoms, and addiction develop
later in life. A challenge with such studies, of course, is attrition, and
thus cohorts need to heavily invest in reducing participant loss in their
studies. A possible solution to this challenge is using registry data: some
countries, particularly the Nordic countries, have nationwide registries
(Lund and Bukten, 2015) that are well-suited for longitudinal studies.
The registries include comprehensive information about each citizen
over the course of their lives, including detailed demographic in-
formation (e.g. education, employment, marital status, all birth and
death dates), and health care utilization (e.g., contacts with primary
health care, specialist health care, dispensed prescription medications).
In some countries, information from the various registries can be
combined at the individual and family level using the personal identi-
ﬁcation numbers that are assigned to each person at birth. However,
despite many advantages with nationwide registries, they are not al-
ways able to identify risks associated with prenatal exposure to legal
and illegal substances, as often this is not documented in the registries
(except in cases with a parental substance use disorder). Importantly,
though, most women using cannabis during pregnancy do not have a
cannabis use disorder diagnosis registered in their medical record.
Thus, only a small proportion will be identiﬁed with this approach. One
solution to identify cannabis-using women who do not have a cannabis
use disorder is to combine pregnancy cohort surveys with registry data.
This would be possible if survey respondents are also asked to provide
their personal identiﬁcation numbers and provide consent to match
information from the survey(s) to registry data. This approach has
several advantages: depending on the survey questions, it can provide
detailed information on maternal cannabis use and other substance use
during pregnancy. Further, since follow-up can be done in registries,
issues with loss to follow-up will be non-existent or negligible.
Second, to inform public health policy regarding the eﬀect of pre-
natal exposure to cannabis on subsequent child outcomes, future studies
that diﬀerentiate between causal and non-causal associations are ne-
cessary. Determining causality is diﬃcult given that many women who
use cannabis also use other substances (Coleman-Cowger et al., 2017;
Gunn et al., 2016; Hasin, 2017; Washio et al., 2018). In addition, using
cannabis in pregnancy is related to many socioeconomic and psycho-
social indicators (El Marroun et al., 2008), which confound the asso-
ciation of prenatal cannabis exposure and maternal and child health
outcomes. If associations are presented as causal associations when they
are not, this may result in misguided interventions that are a waste of
resources and distract attention from eﬀective methods (Smith, 2008).
To address unmeasured or residual confounding, several innovative
study designs could be used. For instance, quasi-experimental designs
are able to control for unmeasured familial risk factors (D'Onofrio et al.,
2013; Hill et al., 2000). Mendelian Randomization (MR) is an exciting
and innovative technique that was proposed in 1986, but only recently
became viable following advances in the ﬁeld of genetics. MR utilizes
genetic variation strongly associated with a predictor variable, as a
proxy or ‘instrument’ to test causal eﬀects on a speciﬁed outcome
variable. For example, genetic variants that modify the biological re-
sponse to an environmental exposure—such as genetic variants related
to alcohol metabolism can be taken as indicators of the eﬀects of dif-
ferent levels of exposure (Smith and Ebrahim, 2004). In addition, a
recent genome-wide association study has identiﬁed multiple genetic
variants related to lifetime cannabis use (Pasman et al., 2018). Typi-
cally, observational studies are weakened by residual confounding and
reverse causation, and bidirectional MR designs can be used to account
for reverse causality and residual confounding (Davey Smith and
Ebrahim, 2003). Other instrumental variable methods are also well-
suited to overcome unmeasured confounding in epidemiological studies
(Davies et al., 2017), for example using a negative control. Studies
using paternal cannabis exposure as a negative exposure may give in-
sights into the role of potential shared familial confounding and genetic
predisposition (Smith, 2008). When mothers use cannabis during
pregnancy almost all fathers/partners use cannabis as well. However,
when fathers use cannabis, only 10% of the mothers use cannabis. This
has been previously shown in the Generation R study, and thus can-
nabis use by the father or partner is suitable to account for non-in-
trauterine eﬀects of cannabis use. Finally, a promising approach is using
a sibling design in which family factors are controlled for. However,
discordant siblings (i.e., being exposed and unexposed to cannabis) are
rare, and statistical power is a common limitation of this approach
(Frisell et al., 2012). Moreover, if the siblings are discordant on the
exposure, they may also be discordant on other variables, which may
lead to bias.
Finally, future research should examine the role of policies (e.g.,
medical and recreational cannabis laws) on prenatal cannabis use.
Cannabis use during pregnancy has been increasing (Brown et al.,
2017b) in the context of US states adopting more permissive cannabis
legislation, despite continued federal prohibition of cannabis use. In the
past two decades, more than half of the US states have implemented
medicinal marijuana laws and 8 states plus the District of Columbia
have legalized adult recreational cannabis use. Some evidence suggests
that medical marijuana laws are associated with increased cannabis use
and cannabis use disorder among adults, whereas data are insuﬃcient
to determine the eﬀects of recreational legalization (Carliner et al.,
2017). Other possible consequences of the changing cannabis policy
landscape in the US are potential modiﬁcations in modes of cannabis
use (inhalation through a wide array of devices, vaping, dabbing, or
oral delivery by ingestible oils and edibles), increased potency of can-
nabis products, and increased cannabis availability (Budney and
Borodovsky, 2017). A potential unintentional consequence of increas-
ingly permissive marijuana use laws could be the increased use of high
potency cannabis during and around the time of pregnancy; however,
research has not yet directly examined this hypothesis.
The ‘coﬀee shop system’ in the Netherlands, which is a system that
was introduced in 1976 and does not fully prohibit nor fully legalize use
of cannabis, could give us some hints at what might happen in the US
(MacCoun, 2011). The best available evidence paints a nuanced picture.
Although life-time prevalence in the Netherlands is relatively high
(28.0%), the Dutch ‘continuation rate’ is lower relative to their
H. El Marroun et al. Preventive Medicine 116 (2018) 1–5
3
counterparts in Europe and the United States (MacCoun, 2011).
4. Considerations for clinical practice
4.1. Identiﬁcation of pregnant cannabis users
Healthcare providers have an important opportunity to address
prenatal cannabis use in a prenatal care setting. However, providers
may face a dilemma of having to develop rapport with a pregnant
cannabis-using patient while meeting mandatory requirements to re-
port prenatal substance use to a state agency in some states (Mark and
Terplan, 2017). Developing rapport and therapeutic relationship with
healthcare providers is essential to reduce fear of stigmatization or
other consequences and increase disclosure of use (Mark and Terplan,
2017; McLaﬀerty et al., 2016). Providers must also be educated in order
to inform their pregnant patients on possible medical, social, and legal
consequences of cannabis use while empathizing and attenuating the
feeling of guilt or shame related to their cannabis use (McLaﬀerty et al.,
2016). Sole use of biochemical screening to identify prenatal substance
use might not be ideal, since it may interfere with the process of de-
veloping a therapeutic relationship with a patient who screened posi-
tive for use while denying the use (Terplan, 2012). Further, sole use of
urine screening, does not provide a comprehensive estimate of cannabis
use in pregnancy. The combination of self-reported information with
urinalysis is needed to improve the quality of cannabis use assessment
as self-reported information may add information on frequency, quan-
tity and products used (El Marroun et al., 2011; Young-Wolﬀ et al.,
2017). Further, THC detection using urine, blood, saliva or hair is
possible (Musshoﬀ and Madea, 2006; Teixeira et al., 2007), but these
methods do not provide accurate information on timing of cannabis use
during pregnancy. Therefore, Screening, Brief Intervention, and Re-
ferral to Treatment (SBIRT) if necessary may be ideal to identify pre-
natal cannabis use and engage women in a discussion of their use, in-
cluding reasons for use, providing feedback on the possible
consequences of prenatal cannabis use, discouraging cannabis use and
encourage additional treatment as appropriate. Because many women
who report prenatal cannabis use also tend to smoke tobacco while
pregnant, providers should be prepared to address both cannabis and
tobacco use (Coleman-Cowger et al., 2017).
4.2. Barriers to medical providers
Notably, providers state that they lack knowledge of deﬁnitive
health risks of cannabis use during and around the time of pregnancy
(Holland et al., 2016). Therefore, health care provider education is
needed on the risks of cannabis use on reproductive health. A targeted
approach to treating prenatal cannabis use should be developed, as this
area remains under developed (McLaﬀerty et al., 2016). Further, to
promote optimal maternal and child health, states should dismantle
mandatory reporting laws that criminalize women for prenatal sub-
stance use. Punitive laws discourage women from disclosing use of
cannabis (or other substances) during prenatal check-ups, ultimately
leading to missing opportunities for treatment and prevention. Such
laws have been demonstrated to be ineﬀective and inappropriate
(ACOG, 2011). Finally, the environmental context should also be con-
sidered as cannabis use may be serving speciﬁc functions for pregnant
women (e.g., relief of nausea (Westfall, 2004; Westfall et al., 2006), or
potentially reducing anxiety or stress), that must be addressed in con-
junction with the recommendations for abstinence from cannabis use by
the American Congress of Obstetricians and Gynecologists (Committee
on Obstetric Practice, 2017). Considering that cannabis use is dis-
couraged during preconception, pregnancy, and lactation (ACOG,
2015), health care providers should have a discussion about cannabis
use with all women of reproductive age, including those who are
planning for pregnancy and those who are postpartum.
5. Summary
The aim of narrative review was to describe the ﬁndings from epi-
demiological and developmental perspectives, and to provide sugges-
tions for future studies and clinical practice. Cannabis use in pregnancy
poses major health concerns for pregnant mothers and their developing
children. Although studies on the short- and long-term consequences of
prenatal cannabis exposure are increasing, ﬁndings have been incon-
sistent or diﬃcult to interpret due to methodological issues. Thus,
consolidating these ﬁndings into clinical recommendations based on
the mixed studies in the literature remains a challenge. Synthesizing the
available observational studies is also diﬃcult, because the published
studies have substantial methodological weaknesses and gaps remain in
the literature. Improving observational studies and addressing un-
answered questions will be important steps toward understanding the
extent to which prenatal exposure to cannabis inﬂuences neurodeve-
lopment in the oﬀspring.
In conclusion, further research on prenatal cannabis exposure and
the long-term consequences to oﬀspring health in representative sam-
ples are needed to guide and improve clinical care for pregnant women
and their children. Future research should also investigate the role of
policies on prenatal cannabis use.
Acknowledgments
We thank the organizing committee of the 10th Annual
International Women's and Children's Health and Gender (InWomen's)
Group Conference in June 2017 in Montreal, and in particular
Conference Chair Dr. Wendee Wechsberg, because this event was the
starting point of this manuscript. Dr. Hanan El Marroun was supported
by Stichting Volksbond Rotterdam, the Dutch Brain Foundation (De
Hersenstichting, project number GH2016.2.01) and the European
Union's Horizon 2020 research and innovation programme (grant
agreement No. 633595 DynaHEALTH and No. 733206 LifeCycle). The
funding agencies had no role in the design or conduct of the study,
interpretation or preparation, review or approval of the manuscript or
the decision to submit it for publication.
Conﬂict of interest statement
All authors declare that they have no competing interests.
References
ACOG, 2011. AGOG Committee Opinion No. 473: substance abuse reporting and preg-
nancy: the role of the obstetrician-gynecologist. Obstet. Gynecol. 117, 200–201 2 pp.
ACOG, 2015. Committee Opinion No. 637: marijuana use during pregnancy and lactation.
Obstet. Gynecol. 126, 234–238.
Beatty, J.R., Svikis, D.S., Ondersma, S.J., 2012. Prevalence and perceived ﬁnancial costs
of marijuana versus tobacco use among urban low-income pregnant women. J.
Addict. Res. Ther. 3, 1000135.
Bergeria, C.L., Heil, S.H., 2015. Surveying lactation professionals regarding marijuana use
and breastfeeding. Breastfeed. Med. 10, 377–380.
Brown, Q.L., Sarvet, A., Hasin, D., 2017a. Prenatal marijuana use, psyhciatric co-
morbidity, and vulnerable populations in the US. In: 79th Annual Meeting of the
College on Problems of Drug Dependence. Montreal, Canada.
Brown, Q.L., Sarvet, A.L., Shmulewitz, D., Martins, S.S., Wall, M.M., Hasin, D.S., 2017b.
Trends in marijuana use among pregnant and nonpregnant reproductive-aged
women, 2002–2014. JAMA 317, 207–209.
Budney, A.J., Borodovsky, J.T., 2017. The potential impact of cannabis legalization on the
development of cannabis use disorders. Prev. Med. 104, 31–36.
Calvigioni, D., Hurd, Y.L., Harkany, T., Keimpema, E., 2014. Neuronal substrates and
functional consequences of prenatal cannabis exposure. Eur. Child Adolesc.
Psychiatry 23, 931–941.
Carliner, H., Brown, Q.L., Sarvet, A.L., Hasin, D.S., 2017. Cannabis use, attitudes, and
legal status in the U.S.: a review. Prev. Med. 104, 13–23.
Coleman-Cowger, V.H., Schauer, G.L., Peters, E.N., 2017. Marijuana and tobacco co-use
among a nationally representative sample of US pregnant and non-pregnant women:
2005–2014 National Survey on Drug Use and Health ﬁndings. Drug Alcohol Depend.
177, 130–135.
Committee on Obstetric Practice, 2017. Committee opinion no. 722: marijuana use during
pregnancy and lactation. Obstet. Gynecol. 130, e205–e209.
H. El Marroun et al. Preventive Medicine 116 (2018) 1–5
4
Davey Smith, G., Ebrahim, S., 2003. ‘Mendelian randomization’: can genetic epide-
miology contribute to understanding environmental determinants of disease? Int. J.
Epidemiol. 32, 1–22.
Davies, N.M., Thomas, K.H., Taylor, A.E., Taylor, G.M., Martin, R.M., Munafo, M.R.,
Windmeijer, F., 2017. How to compare instrumental variable and conventional re-
gression analyses using negative controls and bias plots. Int. J. Epidemiol. 46,
2067–2077.
Djulus, J., Moretti, M., Koren, G., 2005. Marijuana use and breastfeeding. Can. Fam.
Physician 51, 349–350.
D'Onofrio, B.M., Lahey, B.B., Turkheimer, E., Lichtenstein, P., 2013. Critical need for
family-based, quasi-experimental designs in integrating genetic and social science
research. Am. J. Public Health 103 (Suppl. 1), S46–S55.
Dujourdy, L., Besacier, F., 2017. A study of cannabis potency in France over a 25 years
period (1992–2016). Forensic Sci. Int. 272, 72–80.
El Marroun, H., Tiemeier, H., Jaddoe, V.W., Hofman, A., Mackenbach, J.P., Steegers, E.A.,
Verhulst, F.C., van den Brink, W., Huizink, A.C., 2008. Demographic, emotional and
social determinants of cannabis use in early pregnancy: the Generation R study. Drug
Alcohol Depend. 98, 218–226.
El Marroun, H., Tiemeier, H., Jaddoe, V.W., Hofman, A., Verhulst, F.C., van den Brink,
W., Huizink, A.C., 2011. Agreement between maternal cannabis use during preg-
nancy according to self-report and urinalysis in a population-based cohort: the
Generation R Study. Eur. Addict. Res. 17, 37–43.
El Marroun, H., Tiemeier, H., Franken, I.H., Jaddoe, V.W., van der Lugt, A., Verhulst, F.C.,
Lahey, B.B., White, T., 2016. Prenatal cannabis and tobacco exposure in relation to
brain morphology: a prospective neuroimaging study in young children. Biol.
Psychiatry 79, 971–979.
Frisell, T., Oberg, S., Kuja-Halkola, R., Sjolander, A., 2012. Sibling comparison designs:
bias from non-shared confounders and measurement error. Epidemiology 23,
713–720.
Gunn, J.K., Rosales, C.B., Center, K.E., Nunez, A., Gibson, S.J., Christ, C., Ehiri, J.E., 2016.
Prenatal exposure to cannabis and maternal and child health outcomes: a systematic
review and meta-analysis. BMJ Open 6, e009986.
Hasin, D.S., 2017. U.S. epidemiology of cannabis use and associated problems.
Neuropsychopharmacology 43, 195–212.
Hill, S.Y., Lowers, L., Locke-Wellman, J., Shen, S.A., 2000. Maternal smoking and
drinking during pregnancy and the risk for child and adolescent psychiatric disorders.
J. Stud. Alcohol 61, 661–668.
Holland, C.L., Nkumsah, M.A., Morrison, P., Tarr, J.A., Rubio, D., Rodriguez, K.L.,
Kraemer, K.L., Day, N., Arnold, R.M., et al., 2016. “Anything above marijuana takes
priority”: obstetric providers' attitudes and counseling strategies regarding perinatal
marijuana use. Patient Educ. Couns. 99, 1446–1451.
Huizink, A.C., 2014. Prenatal cannabis exposure and infant outcomes: overview of stu-
dies. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 52, 45–52.
Jutras-Aswad, D., Dinieri, J.A., Harkany, T., Hurd, Y.L., 2009. Neurobiological con-
sequences of maternal cannabis on human fetal development and its neuropsychiatric
outcome. Eur. Arch. Psychiatry Clin. Neurosci. 259, 395–412.
Ko, J.Y., Farr, S.L., Tong, V.T., Creanga, A.A., Callaghan, W.M., 2015. Prevalence and
patterns of marijuana use among pregnant and nonpregnant women of reproductive
age. Am. J. Obstet. Gynecol. 213, 201.e1–201.e10.
Lubman, D.I., Cheetham, A., Yucel, M., 2015. Cannabis and adolescent brain develop-
ment. Pharmacol. Ther. 148, 1–16.
Lund, I.O., Bukten, A., 2015. Harm to others from substance use and abuse: the underused
potential in nationwide registers. Subst. Abus. 9, 33–38.
MacCoun, R.J., 2011. What can we learn from the Dutch cannabis coﬀeeshop system?
Addiction 106, 1899–1910.
Mark, K., Terplan, M., 2017. Cannabis and pregnancy: maternal child health implications
during a period of drug policy liberalization. Prev. Med. 104, 46–49.
McLaﬀerty, L.P., Becker, M., Dresner, N., Meltzer-Brody, S., Gopalan, P., Glance, J.,
Victor, G.S., Mittal, L., Marshalek, P., et al., 2016. Guidelines for the management of
pregnant women with substance use disorders. Psychosomatics 57, 115–130.
McLemore, G.L., Richardson, K.A., 2016. Data from three prospective longitudinal human
cohorts of prenatal marijuana exposure and oﬀspring outcomes from the fetal period
through young adulthood. Data Brief 9, 753–757.
Miller, B.L., Stogner, J.M., Miller, J.M., 2016. Exploring butane hash oil use: a research
note. J. Psychoactive Drugs 48, 44–49.
Musshoﬀ, F., Madea, B., 2006. Review of biologic matrices (urine, blood, hair) as in-
dicators of recent or ongoing cannabis use. Ther. Drug Monit. 28, 155–163.
National Academies of Sciences, Engineering, and Medicine, Health and Medicine
Division, Board on Population Health and Public Health Practice, Committee on the
Health Eﬀects of Marijuana: An Evidence Review and Research Agenda, 2017. The
Health Eﬀects of Cannabis and Cannabinoids: The Current State of Evidence and
Recommendations for Research. Washington (DC).
Niesink, R.J., Rigter, S., Koeter, M.W., Brunt, T.M., 2015. Potency trends of Delta9-tet-
rahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands:
2005–15. Addiction 110, 1941–1950.
Pasman, J.A., Verweij, K.J.H., Gerring, Z., Stringer, S., Sanchez-Roige, S., Treur, J.L.,
Abdellaoui, A., Nivard, M.G., Baselmans, B.M.L., et al., 2018. Genome-wide asso-
ciation analysis of lifetime cannabis use (N=184,765) identiﬁes new risk loci, ge-
netic overlap with mental health, and a causal inﬂuence of schizophrenia on cannabis
use. In: bioRxiv.
de Salas-Quiroga, A., Diaz-Alonso, J., Garcia-Rincon, D., Remmers, F., Vega, D., Gomez-
Canas, M., Lutz, B., Guzman, M., Galve-Roperh, I., 2015. Prenatal exposure to can-
nabinoids evokes long-lasting functional alterations by targeting CB1 receptors on
developing cortical neurons. Proc. Natl. Acad. Sci. U. S. A. 112, 13693–13698.
Smith, G.D., 2008. Assessing intrauterine inﬂuences on oﬀspring health outcomes: can
epidemiological studies yield robust ﬁndings? Basic Clin. Pharmacol. Toxicol. 102,
245–256.
Smith, G.D., Ebrahim, S., 2004. Mendelian randomization: prospects, potentials, and
limitations. Int. J. Epidemiol. 33, 30–42.
Smith, A.M., Fried, P.A., Hogan, M.J., Cameron, I., 2006. Eﬀects of prenatal marijuana on
visuospatial working memory: an fMRI study in young adults. Neurotoxicol. Teratol.
28, 286–295.
Smith, A.M., Longo, C.A., Fried, P.A., Hogan, M.J., Cameron, I., 2010. Eﬀects of mar-
ijuana on visuospatial working memory: an fMRI study in young adults.
Psychopharmacology 210, 429–438.
Teixeira, H., Verstraete, A., Proenca, P., Corte-Real, F., Monsanto, P., Vieira, D.N., 2007.
Validated method for the simultaneous determination of Delta9-THC and Delta9-
THC-COOH in oral ﬂuid, urine and whole blood using solid-phase extraction and
liquid chromatography-mass spectrometry with electrospray ionization. Forensic Sci.
Int. 170, 148–155.
Terplan, M., 2012. Commentary on Ondersma et al. (2012): beyond the quest for the
perfect test-drug use screening in pregnancy. Addiction 107, 2107–2108.
Trezza, V., Cuomo, V., Vanderschuren, L.J., 2008. Cannabis and the developing brain:
insights from behavior. Eur. J. Pharmacol. 585, 441–452.
Varner, M.W., Silver, R.M., Rowland Hogue, C.J., Willinger, M., Parker, C.B., Thorsten,
V.R., Goldenberg, R.L., Saade, G.R., Dudley, D.J., et al., 2014. Association between
stillbirth and illicit drug use and smoking during pregnancy. Obstet. Gynecol. 123,
113–125.
Warshak, C.R., Regan, J., Moore, B., Magner, K., Kritzer, S., Van Hook, J., 2015.
Association between marijuana use and adverse obstetrical and neonatal outcomes. J.
Perinatol. 35, 991–995.
Washio, Y., Mark, K., Terplan, M., 2018. Characteristics of pregnant women reporting
cannabis use disorder at substance use treatment entry. J. Addict. Med (Epub ahead
of print).
Westfall, R.E., 2004. Use of anti-emetic herbs in pregnancy: women's choices, and the
question of safety and eﬃcacy. Complement. Ther. Nurs. Midwifery 10, 30–36.
Westfall, R.E., Janssen, P.A., Lucas, P., Capler, R., 2006. Survey of medicinal cannabis use
among childbearing women: patterns of its use in pregnancy and retroactive self-
assessment of its eﬃcacy against ‘morning sickness’. Complement. Ther. Clin. Pract.
12, 27–33.
Wu, C.S., Jew, C.P., Lu, H.C., 2011. Lasting impacts of prenatal cannabis exposure and the
role of endogenous cannabinoids in the developing brain. Future Neurol. 6, 459–480.
Young-Wolﬀ, K.C., Tucker, L.Y., Alexeeﬀ, S., Armstrong, M.A., Conway, A., Weisner, C.,
Goler, N., 2017. Trends in self-reported and biochemically tested marijuana use
among pregnant females in California from 2009–2016. JAMA 318, 2490–2491.
H. El Marroun et al. Preventive Medicine 116 (2018) 1–5
5
